The treatment, Caplyta, is the drug developer's lead candidate that
has shown to regulate three neurotransmitter systems associated to
severe mental illnesses - serotonin, dopamine and glutamate.
Schizophrenia is a chronic mental disorder that causes distortion in
thoughts, hallucinations and feelings of fright and paranoia.
(Reporting by Trisha Roy in Bengaluru; Editing by Maju Samuel)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |